RT Journal Article
SR Electronic
T1 Novel multiplex tools in an epidemic panel improve prediction of RSV infection dynamics and disease burden – a RESPINOW analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.20.24317653
DO 10.1101/2024.11.20.24317653
A1 Harries, Manuela
A1 Klett-Tammen, Carolina J.
A1 Rodiah, Isti
A1 Dulovic, Alex
A1 Jaeger, Veronika K
A1 Krepel, Jessica
A1 Contreras, Sebastian
A1 Maak, Katrin
A1 Marsall, Patrick
A1 Möller, Annette
A1 Heise, Jana-Kristin
A1 Castell, Stefanie
A1 RESPINOW study group
A1 Schneiderhan-Marra, Nicole
A1 Karch, André
A1 Lange, Berit
YR 2024
UL http://medrxiv.org/content/early/2024/11/23/2024.11.20.24317653.abstract
AB Respiratory Syncytial Virus (RSV) is one of the leading causes of morbidity and mortality among infants and adult risk groups worldwide. Substantial case-underdetection and gaps in the understanding of reinfection dynamics of RSV limit reliable projection estimates.Here, we use a novel RSV multiplex serological assay in a population-based panel to estimate season and age-specific probability of reinfection and combine it with sentinel and notification data to parameterize a mathematical model tailored to project RSV dynamics in Germany from 2020 to 2023.Our reinfection estimates, based on a 20% post-F and a 45% N antibody increase in the assay over consecutive periods, were 5·7% (95%CI: 4·7-6·9) from 2020 to 2022 and 12·7% (95%CI: 10·5-15·2) from 2022 to 2023 in adults. In 2021, 30-39 year olds had a higher risk of reinfection, whereas in 2022, all but the 30-39 age group had an increased risk of reinfection. This suggests age-differential infection acquisition in the two seasons, e.g. due to still stronger public health measures in place in 2021 than in 2022.Model-based projections that include the population-based reinfection estimations predicted the onset and peak for the 23/24 RSV season better than those only based on surveillance estimates.Rapid, age-specific reinfection assessments and models incorporating this data will be critical for understanding and predicting RSV dynamics, especially with changing post-pandemic patterns and new prevention strategies e.g. monoclonal antibody.Helmholtz Association, EU Horizon 2020 research and innovation program, Federal Ministry of Education and Research, and German Research supported this work.Competing Interest StatementBerit Lange: Member of the Expert Council Health and Resilience, Federal Chancellery Member of the Standing Vaccination Commission at the Robert Koch Institute Elected (Deputy) President of the German Society for Epidemiology (DGEpi), deputy in 2023 and 2026, president in 2024 and 2025 Part of the pool of experts of the Federal Ministry of Education and Research (BMBF) for consultations on pandemic preparedness and the overall responsiveness of health research to health crises Member of the Advisory Board for the Pact for Public Health (Pakt OEGD), Federal Ministry of Health (BMG) Nicole Schneider-MArra: Travel support from Luminex/Diasorin for panel head at the xMAP Connect Meeting 2023 Funding StatementThe Helmholtz Association, European Union's Horizon 2020 research and innovation program [grant number 101003480], the Federal Ministry of Education and Research (BMBF) as part of the Network University Medicine (NUM) via the egePan Unimed project (grant number: 01KX2021), the IMMUNEBRIDE project (grant number: 01KX2121) and the PREPARED project (grant number: 01KX2121), the Federal Ministry of Education and Research (BMBF) via the RESPINOW (grant number: HZI MV2021-012, NMI FKZ031L0298B) and OptimAgent (grant number: MV2021-014) projects, by the German Research Foundation (DFG) via the SpaceImpact (grant number: KA 5361/7-1), and Epiadaptdiag (grant number: KA 5361/1-1) projects as well as by intramural HZI funds supported this work. The NAKO is funded by the Federal Ministry of Education and Research (BMBF) [project funding reference numbers: 01ER1301A/B/C, 01ER1511D, 01ER1801A/B/C/D and 01ER2301A/B/C], federal states of Germany and the Helmholtz Association, the participating universities and the institutes of the Leibniz Association. The NMI receives funding from the Baden-Wurttemberg Ministry of Economic Affairs, Labor and Tourism (Germany).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Hannover Medical School (9086_BO_S_2020 for MuSPAD)approved the MuSPAD and RESPINOW StudyI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://serohub.net/